Immune Checkpoint Inhibitor (ICI) therapies based on TME have made many achievements, such as programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and CTLA4 checkpoint inhibitors, which have revolutionized the treatment of NSCLC in the last decade [16,17]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.